Abstract: A compression dressing is disclosed. The compression dressing comprises a self-adhering elastic bandage strip designed for exerting a compressive force when wrapped around a body part sufficient to hold the compression dressing in place for a period of time to provide a therapeutic effect to a wound and an absorbent pad affixed to an inner side of a terminal portion or to a terminal end of the self-adhering elastic bandage strip.

Abstract: A distance measurement system, comprising at least one resonant circuit, at least one magnetic element with predetermined magnetic properties, a transmitter operable to transmit an electromagnetic pulse, a receiver operable to detect oscillations emitted by said resonant circuit in response to said electromagnetic pulse, and an analyzer operable to analyze an amplitude envelope property of said oscillations, to thereby determine a distance between the resonant circuit and the magnetic element.

Abstract: A VTOL aircraft (or other vehicle such as a sea vehicle) includes a pair of elongated ducts on opposite sides of the vehicle body, and a plurality of powered propellers (or other propulsion units such as jet engines) mounted within and enclosed by each of the elongated ducts, such as to produce an upward lift force to the vehicle. Each of the elongated ducts has a short transverse dimension slightly larger than the diameter of the blades of each propeller enclosed thereby, and a large transverse dimension slightly larger than the sum of the diameters of the blades of all the propellers enclosed thereby.

Abstract: Intravascular apparatus and method for locally treating a patient's blood vessel, are provided. The apparatus includes an implanted carrier (2) for insertion into the vessel; and a biologically active agent (8) immobilized to the carrier (2), said biologically active agent (8) reacting with a first substance to produce a second substance. The second substance is preferably a therapeutic agent, such as nitric oxide, for locally treating the vessel. The biologically active agent (8) is preferably an enzyme such as nitrogen oxide synthase, and the first substance is preferably arginine introduced to the patient's body as part of a diet. According to another embodiment, the biologically active agent (8) is a catalytic antibody and the first substance is a prodrug. Alternatively, the biologically active agent (8) is a ribozyme.

Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.

Abstract: A method and system for fabricating electrical heating devices employing positive temperature coefficient (PTC) thermistor as heating elements which includes: assembling the heating devices with PTC thermistor heating elements preselected according to electrical resistance, applying pressure across the interface between the PTC heating elements and the radiator plates of the heating devices during their assembly, and exposing the heating devices for extended periods of time to both ambient and operational temperatures. The method of fabrication further includes continuously monitoring the electrical resistance of the heating devices and holding their electrical resistance stable by adjusting the pressure applied across the interface between the PTC heating elements and the radiator plates.

Abstract: A method and apparatus for controlling a processing machine to perform a processing operation on a workpiece by (a) determining the nominal locations of at least two sensible reference marks on the workpiece in terms of the coordinates of the workpiece; (b) loading the workpiece on the processing machine; (c) sensing, and measuring the actual locations of, the reference marks on the workpiece when so mounted, in terms of the coordinates of the processing machine; (d) determining at least one geometrical transformation needed to transform the workpiece coordinates of the nominal locations of the reference marks to the processing machine coordinates of the actual locations of the reference marks; (e) and controlling the processing machine in accordance with the determined geometrical transformation.

Abstract: A physiotherapeutic device for concurrently applying heat and electrical stimulation to a localized treatment area comprises a heat transfer medium for placing in contact with the treatment area, the heat transfer medium having a heat capacity such that the device is operable to change a temperature of said heat transfer medium from a temperature able to induce a burn to a safe temperature substantially within a minute.

Abstract: A monoclonal antibody elicited by a heparanase protein or an immunogenical portion thereof, the monoclonal antibody specifically inhibits heparanase activity.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: A surgical inserter is provided which includes (a) a head portion formed with a ring acceptor for accepting a ring of the surgical screw; and (b) a neck portion connected to, or integrally formed with, the head portion. The neck portion is formed with two longitudinal grooves for engaging a folded band of connective tissue therein.

Abstract: A spectral bio-imaging method for enhancing pathologic, physiologic, metabolic and health related spectral signatures of an eye tissue, the method comprising the steps of (a) providing an optical device for eye inspection being optically connected to a spectral imager; (b) illuminating the eye tissue with light via the iris, viewing the eye tissue through the optical device and spectral imager and obtaining a spectrum of light for each pixel of the eye tissue; and (c) attributing each of the pixels a color or intensity according to its spectral signature, thereby providing an image enhancing the spectral signatures of the eye tissue.

Abstract: A system and method for rapid video data compression and transmission for a wireless remote monitor. The compression method is adjusted according to the type of software application which generated the video data, and according to the characteristics of the data itself. Preferably, the type and profile of video data compression is selected by a profile manager, which detects the characteristics of the video data to determine the character of the data, and then which selects the video data compression method and profile according to the video data character. The compression method and system may be used with a device for remotely displaying information from a monitor of a main computer and for remotely and fully controlling the main computer.

Abstract: The present invention teaches novel Eps15 homology (EH) domain containing proteins, polynucleotide sequences encoding the novel EH domain containing proteins, oligonucleotides and oligonucleotide analogs derived from the polynucleotide sequences, a display library displaying short peptides derived from the EH domain containing proteins, antibodies recognizing the EH domain containing proteins, peptides or peptide analogs derived from the EH domain containing proteins, and pharmaceutical compositions and methods of employing the peptides or peptide analogs, the oligonucleotides and oligonucleotide analogs, and/or the polynucleotide sequences to up-regulate or down-regulate clathrin coated pit mediated endocytosis and thereby insulin growth factor 1 receptor (IGF1 receptor) signaling.

Abstract: A light reflecting article is disclosed. The light reflecting article comprises a sample carrying article layered with a light reflecting layer. The light reflecting layer serves for allowing an optical collection and detection system to collect both luminescent light emitted from a sample positioned on the light reflecting article in a direction of the optical collection and detection system, as well as luminescent light emitted from the sample in a direction away from the optical collection and detection system and reflected in the direction of the optical collection and detection system via the light reflecting layer, thereby increasing a sensitivity of luminescent light detection.

Abstract: A system and a method for direct communication between a remote ground transceiver and the intended recipient, such as a management station, through a satellite. The disclosed system and method are particularly useful for the rapid transmission of short messages, such as alarm messages, from equipment at remote sites to the management station. Optionally and preferably, messages can also be passed from the management station to the remote site, for example in order to transmit a command, such that a human supervisor at the management station would be able to respond to the alarm message. The messages are rapidly transmitted by passing directly from the satellite to the final recipient The satellite optionally determines the information necessary for billing and optionally passes this information to a ground center for sending the bill to the client.

Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.

Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.

Abstract: Serious hematologic malignancies are treated through high dose or lethal chemotherapy and/or radiation therapy conditioning regimens followed by rescue with allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (ASCT). These myeloablative/lymphoablative (M/L) treatment regimens involve the elimination of both the patient's hematopoietic stem cells and T-lymphocytes, often leading to serious complications including graft versus host disease (GVHD). The claimed invention addresses some of these problems by providing a conditioning regimen that is designed to eliminate the patient's T-lymphocytes while retaining a functional population of hematopoietic stem cells (HSC). This non-myeloablative/lymphoablative (-/L) conditioning regimen involves the administration of one or more agents such as purine analogs (e.g., fludarabine), alkylating agents (e.g., bisulfan, cyclophosphamide), or anti-leukocyte globulins (e.g., anti-T lymphocyte globulin).

Abstract: A method of transplanting a transplant derived from a donor into a recipient is disclosed. The method comprises the steps of (a) transplanting the transplant into the recipient; and (b) administering to the recipient a dose including non-alloreactive anti-third party cytotoxic T-lymphocytes (CTLs), wherein the non-alloreactive anti-third party CTLs are generated by directing T-lymphocytes of the donor against a third party antigen or antigens, the dose is substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, thereby preventing or ameliorating both graft rejection by the recipient and graft versus host disease.